REFERENCES
- Van Leeuwen R. The Atlantic study: a randomized, open-label trial comparing two PI-sparing antiretroviral strategies versus a standard PI-containing regimen, 2 year follow-up data. In: Program and abstracts of the 14th International AIDS Conference; July 7–12, 2002; Barcelona. Abstract MoPeB3089.
- Staszewski S, Morales-Ramirez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865–1873.
- King R, Klabe R, Reid C, Erickson-Viitanen S. Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other HIV NNRTIs, NRTIs, or protease inhibitors. Antimicrob Agents Chemother. 2002;46:1640–1646.
- Deeks S, Hecht F, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13:F35–43.
- Barreiro P, Garcia-Benayas T, Gallant J. The simplification strategy: sustaining success, reducing toxicity and ensur-ing adherence after PI therapy. AIDS Rev. 2002;4:233–241.
- Fisac C, Fumero E, Crespo M, et al. Metabolic and body composition changes in patients switching from a P1-con-taining regimen to ABC, EFV or NVP. Twelve-month results of a randomized study (LIPNEFA). In: Program and ab-stracts of the 14th International AIDS Conference; July 7–12, 2002; Barcelona. Abstract ThPeB7354.
- Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from PI to NVP or to EFV in patients with HIV infection and long-lasting viral suppression. Clin Infect Dis. 2002;32:504–510.
- Ren J, Milton J, Weaver K, Short S, Stuart D, Stammers D. Structural basis for the resilience of efavirenz to drug resis-tance mutations in HIV-1 reverse transcriptase. Structure. 2000;8:1089–1094.
- Cozzi-Lepri A, Phillips A, d'Arminio A, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian cohort of naive to antiretrovirals (I.Co.N.A.) study. J Infect Dis. 2002185: 1062–1069.
- Masquelier B, Neau D, Chêne G, et al. Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA. J Acquir Immune Defic Syndr. 200128: 309–312.
- NOriez M, Soriano V, Martin-Carbonero L, et al. SENC (Spanish Efavirenz vs Nevirapine Comparison) trial: a ran-domized, open-label study in HIV-infected naive individu-als. HIV Clin Trials. 2002;3:186–194.
- Sulkowski M, Thomas D, Mehta S, Chaisson R, Moore R. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy. Role of hepatitis C and B infections. Hepatology. 2002;35:182–189.
- Treisman G, Kaolin A. Neurologic and psychiatric compli-cations of antiretroviral agents. AIDS. 2002;16:1201–1215.